RoslinCT Awarded £7.25 million Scottish Enterprise R&D Grant to Advance Digital Cell Therapy Manufacturing

Contributed by: Business Wire

Logo

Tags

Cardiology

Stem Cells

Biotechnology

Pharmaceutical

Oncology

Health

Genetics

Clinical Trials

Scottish Enterprise

More Like This

RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta

RoslinCT Appoints Professor Sir Peter Mathieson and Alexander Vos as New Non-Executive Directors

RoslinCT and Ayrmid Pharma Ltd. Announce Their Intent to Enter Into a Strategic Partnership to Manufacture FDA Approved Cell Therapy Omisirge® (omidubicel-onlv)

RoslinCT Announces Appointment of Jessica Carmen as Chief Commercial Officer

PR Newswire associated0

A Decade of Cell & Gene Therapy Manufacturing and Major GMP Facility Expansion: Cellex's Track Record of Scalable Excellence

RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)

CCRM, OmniaBio and Avectas Partner to Improve Cell Therapy Manufacturing

Celltrio Secures $15 Million Financial Investment to Accelerate Global Expansion in Cell Culturing and Cell & Gene Therapy Automation